News

The FDA has approved deuruxolitinib as a first-line treatment for adults with moderate to severe alopecia areata (AA). 1 Deuruxolitinib, developed by Sun Pharma, is an oral selective inhibitor of ...
The US Food and Drug Administration (FDA) has approved the oral Janus kinase (JAK) inhibitor deuruxolitinib for the treatment of adults with severe alopecia areata.. The development, which was ...
The FDA approved the oral Janus kinase (JAK) inhibitor deuruxolitinib (Leqselvi) to treat alopecia areata, drugmaker Sun Pharmaceutical announced on Thursday. The approval stipulates use of ...
Leqselvi is now FDA approved for treating severe alopecia areata. Sun Pharma added the oral drug to its pipeline via the $576 million acquisition of Concert Pharmaceuticals last year.
You may know finasteride is a medication commonly used to treat male pattern baldness (androgenetic alopecia). But did you know it comes in different forms?
For the second time in under 3 weeks, the FDA has approved treatment for the inherited genetic disorder characterized by ...
The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...
The FDA has granted accelerated approval to Datroway for adults with previously-treated, locally advanced or metastatic EGFR-mutated NSCLC.
A cancer diagnosis brings many worries, but for 81-year-old Peggy Cook, losing her hair during chemotherapy wasn't one of them. Peggy is the first ...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel ...
For one, consider options with finasteride, says Dr. Green. “It’s an FDA-approved oral medication for hair loss that works by inhibiting the activity of 5-alpha-reductase, an enzyme that converts ...
The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.